文献速递免疫规划传染病防控与疫情报告

减毒心水病疫苗肌内注射在牛、绵羊和安哥拉山羊中的安全性与效力

Safety and efficacy of an attenuated heartwater (Ehrlichia ruminantium) vaccine administered by the intramuscular route in cattle, sheep and Angora goats.
PubMed 文献 · Vaccine · 2020-10-24

本研究在较大规模绵羊、安哥拉山羊和牛群中测试减毒心水病(Ehrlichia ruminantium)疫苗经肌内注射的安全性与效力。肌内接种104个EBs的绵羊和安哥拉山羊无接种反应且完全保护,牛接种106个EBs同样无反应且完全保护。结果表明该疫苗可经肌内途径安全接种并诱导100%保护。

要点

  • 安哥拉山羊肌内接种104个EBs无接种反应且对同源攻击完全保护。
  • 牛肌内接种106个EBs无接种反应且对静脉或蜱同源攻击完全保护。

核心结论

  • 减毒E. ruminantium Welgevonden疫苗可经肌内途径安全接种于安哥拉山羊、绵羊和牛,无临床接种反应且对强毒静脉和同源蜱攻击提供100%保护。

研究设计与样本

  • 在较大规模绵羊、安哥拉山羊和牛群中测试疫苗经静脉和肌内途径接种的安全性与效力,并进行疫苗滴定。
  • 绵羊和山羊滴定使用2 ml含102-105个培养来源活EBs,牛滴定使用5 ml含105-107个EBs。
  • 动物经静脉或肌内接种后接受E. ruminantium同源攻击,攻击方式为饲喂感染蜱或静脉接种感染血液。

主要发现

  • 上述治疗动物及剩余90.3%肌内接种山羊对静脉或蜱攻击均显示100%保护。
  • 绵羊和安哥拉山羊肌内接种104个EBs无接种反应且对静脉或蜱攻击完全保护。
  • 牛肌内接种106个EBs无接种反应且对静脉或蜱同源攻击完全保护。
  • 未接种对照动物攻击后出现严重反应并需土霉素治疗。

关键数值与推荐

  • 绵羊和安哥拉山羊肌内接种104个EBs无接种反应且完全保护。
  • 牛肌内接种106个EBs无接种反应且完全保护。

临床怎么用

  • 安哥拉山羊、绵羊和牛可经肌内途径接种该减毒疫苗,避免静脉接种相关严重反应。
  • 肌内接种剂量需按物种选择:绵羊和安哥拉山羊104个EBs,牛106个EBs。

局限性

  • 研究仅评估同源攻击保护,未报告异源田间分离株的交叉保护数据。
  • 原文未报告更大规模田间试验或长期安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heartwater is an economically important tick-borne disease of ruminants in Africa. The current commercial vaccine uses live Ehrlichia ruminantium from blood of infected sheep, requires antibiotic treatment during infection, needs to be administered intravenously and does not protect against all South African isolates. An attenuated tissue culture vaccine not requiring antibiotic treatment and effective against different field strains in small groups of goats and sheep was reported previously. The objective of the present study was to test safety and efficacy of this vaccine administered by intramuscular (i.m.) inoculation in larger groups of sheep, Angora goats and cattle. Animals were vaccinated via intravenous (i.v.) and i.m. routes and received E. ruminantium homologous challenge by feeding of infected ticks or by i.v. inoculation of infected blood. For vaccine titration in sheep and goats, the optimum safe and efficacious dose was determined using 2 ml equivalent of 102-105 culture-derived live elementary bodies (EBs). Similarly, the vaccine was titrated in cattle using 5 ml containing 105-107 EBs. Seventy percent of i.v. vaccinated and 9.7% of i.m. vaccinated Angora goats receiving 105 EBs, developed severe reactions to vaccination and were treated. These treated animals and the remaining 90.3% of i.m.- vaccinated goats showed 100% protection against i.v. or tick challenge. Sheep and Angora goats vaccinated i.m. with 104 EBs had no vaccination reactions and were fully protected against i.v. or tick challenge. Similarly, vaccinated cattle (dose 106 EBs) did not react to vaccine inoculation and were fully protected against i.v. or tick homologous challenge. Control non-vaccinated animals reacted severely to challenge and required oxytetracycline treatment. This successfully demonstrated that Angora goats, sheep and cattle can be safely vaccinated with the attenuated E. ruminantium Welgevonden vaccine via the i.m. route, with no clinical reactions to vaccination and 100% protection against virulent i.v. and homologous tick challenge.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Latif AA, Steyn HC, Josemans AI, et al. Safety and efficacy of an attenuated heartwater (Ehrlichia ruminantium) vaccine administered by the intramuscular route in cattle, sheep and Angora goats. Vaccine. 2020. PMID: 33109388. doi:10.1016/j.vaccine.2020.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。